CRISPR
12 November 2024 The patents have been officially revoked following the pair's voluntary decision to withdraw them | Withdrawal follows unfavourable preliminary opinion from the EPO | Cancelled patents not expected to impact ongoing licensing agreements for CRISPR technology, says licensor.
14 December 2023
14 December 2023
21 February 2023
Latest Features
Big Pharma
The search for clarity goes on as Broad gears up for another set of legal challenges, as Claire Irvine, partner at HGF, explains.
Americas
A former Johnson & Johnson IP counsel and a retired judge are among the speakers at Life Sciences IP Due Diligence, on November 29 and 30 in Boston, as LSIPR finds out.
Americas
Several recent cases from the US Court of Appeals for the Federal Circuit offer guidance on navigating the §101 legal framework with respect to CRISPR patent claims, as Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report.
Americas
Stephen Knight was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.
Biotechnology
As the Broad Institute faces a formidable task in defending its revoked CRISPR patent claims in a pending appeal at the EPO, European academics Jakob Wested, Timo Minssen, and Esther van Zimmeren are wondering whether some of the issues might be referred to the Enlarged Board of Appeal.
Americas
Balancing a company’s duty to shareholders with the public responsibility to provide lifesaving treatments is a constant challenge, as Issi Rozen, chief business officer at the Broad Institute of MIT and Harvard, tells LSIPR.
Americas
As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.
Americas
Jennifer Doudna was selected in the LSIPR 50 2017 publication for her influence on the life sciences industry. She featured in the business and innovation section, as LSIPR reports.
More News
1 March 2022 Patents core to the breakthrough gene-editing technology CRISPR belong to the University of Harvard and the Massachusetts Institute of Technology’s Broad Institute, the US Patent and Trademark Office has ruled.
1 June 2021 A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
25 May 2021 The University of California Berkeley has lost a CRISPR patent in Europe in the latest twist in the long-running IP saga over the gene-editing technology.
9 November 2020 The European Patent Office has released the long-awaited reasoning for its decision to uphold the revocation of a Broad Institute CRISPR/Cas9 patent.
In January this year, the EPO’s Board of Appeal concluded that the Broad’s patent, EP2,771,468, lacked novelty due to an invalid claim to priority.
The EPO dealt with three questions in its reasoning.
28 October 2020 Discretionary denials at the Patent Trial and Appeal Board, the CRISPR landscape and section 101 are top of mind for Eldora Ellison, director at Sterne Kessler Goldstein & Fox.
8 October 2020 French microbiologist Emmanuelle Charpentier and US biochemist Jennifer Doudna have achieved scientific history by jointly winning the Nobel Prize in chemistry for their seminal work on gene-editing technology, CRISPR.
23 September 2020 ERS Genomics, the company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, has appointed Michael Arciero as vice-president of IP and commercial development.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox